Consensus and controversies in platelet transfusion.
Platelet transfusion therapy is the standard of care for thrombocytopenic patients with hemato-oncological disorders and bone marrow failure states due to intensive chemoradiotherapy. Guidelines to lower triggers for prophylactic and therapeutic transfusions are being developed based on better levels of evidence. The optimum transfusion dose, the choice of platelet concentrate and transfusion interval pose a challenge to balance scientific advances with cost-effective strategies. Platelet refractoriness requires "matched" platelets and is a difficult to treat phenomenon. Pathogen inactivation is a crucial issue in view of susceptibility of platelet concentrates to bacterial contamination. This article reviews the current developments and challenges in optimizing platelet transfusion therapy.
Marwaha
Neelam
N
Department of Transfusion Medicine, PGIMER, Chandigarh, India. neelam2918@yahoo.com
Sharma
R R
RR
D001781:Blood Component Removal / Q000379:methods; D032921:Consensus; D006801:Humans; D017713:Platelet Transfusion / Q000379:methods* / Q000592:standards*